The Promise of CRISPR and Next-Generation Cell Therapy
Australia’s biotechnology sector is at the forefront of a therapeutic revolution powered by gene editing and cellular immunotherapy. The convergence of CRISPR-based gene editing, CAR T-cell engineering, and advanced manufacturing is creating new treatment paradigms for cancers and genetic diseases that were previously considered intractable.
The Peter MacCallum Cancer Centre’s “precision guided” CAR T-cell therapy represents a significant advance in this field. In July 2026, the project received $17.7 million in Frontier Health and Medical Research Grant funding from the Medical Research Future Fund (MRFF) to progress to first-in-human clinical trials.
Precision Guided CAR T: Engineering Better Killing
The technology, developed by Professors Paul Beavis and Jane Oliaro, uses CRISPR gene editing to engineer CAR T-cells with enhanced efficacy and improved safety profiles. Compared to conventional CAR T-cells, “Precision Guided Munition” (PGM) CAR T-cells are designed to localise the cytokine response directly into the targeted tumour site.
“A cytokine is a chemical messenger that immune cells use to talk to each other and coordinate a response,” Professor Beavis explains. “Our technique can precisely deliver a cytokine payload directly into the tumour site, resulting in enhanced tumour killing and reduced toxicity”.
The therapy will be clinically trialled first in multiple myeloma—a blood cancer diagnosed in over 2,700 Australians annually with a five-year survival rate of 61%—as a validating step toward later trials in solid tumours, likely breast or lung cancer. The clinical product will be manufactured on-site by Cell Therapies Pty Ltd, a GMP-licensed facility co-located with Peter Mac.
A paper describing the PGM CAR T technology, titled Rewiring endogenous genes in CAR T-cells for tumour-restricted payload delivery, was published in Nature in July 2025, underscoring the scientific rigour underpinning the clinical program.
The KOALA Trial and Kappa Myeloma Antigen Targeting
In parallel with the PGM CAR T program, Peter MacCallum Cancer Centre and Australian biotechnology company HaemaLogiX have advanced a separate CAR T-cell therapy into clinical testing. The KOALA trial is a first-in-human study evaluating KMCAR T-cell therapy targeting the Kappa Myeloma Antigen (KMA) in patients with relapsed or refractory kappa-restricted multiple myeloma.
The first patient was dosed in August 2026, marking a significant milestone for Australian-developed cell therapy. The trial is being conducted at Peter MacCallum Cancer Centre, with clinical doses manufactured at Cell Therapies’ GMP-licensed facility.
This program demonstrates the integration of Australian research, clinical infrastructure, and manufacturing capability in advancing cell therapies from discovery to patient treatment.
Gene Editing for Rare Genetic Diseases
Beyond oncology, Australian researchers are applying gene editing technologies to rare genetic diseases. The Sydney-based St Vincent’s Institute (SVI) has secured $5 million in MRFF Stem Cell Therapies Mission funding to progress a gene editing program for rare bone marrow failure syndromes. The NEXTPAGE project aims to offer a safer and more effective alternative by correcting a patient’s own blood-forming stem cells using advanced gene editing.
At the University of Queensland, researchers have been named a key node in the new Medical Research Council Centre of Research Excellence for Mitochondrial Genome Therapeutics. A personalised therapy was designed in just seven months to correct a misspelled letter in a baby’s mitochondrial DNA using CRISPR gene editing technology.
The speed of this personalised therapy development illustrates the transformative potential of gene editing platforms when combined with rapid genomic diagnostics and agile manufacturing.
The VVMF Milestone: Sovereign Viral Vector Manufacturing
A critical enabler of gene and cell therapy development is the availability of viral vectors—the delivery vehicles that carry therapeutic genetic material into cells. In September 2026, a Sydney company became the first in Australia to earn a manufacturing licence for viral vectors from the Therapeutic Goods Administration.
The Viral Vector Manufacturing Facility (VVMF) milestone strengthens Australia’s capacity to make advanced gene and cell therapies domestically rather than relying on overseas suppliers. This sovereign capability is essential for clinical trial execution and commercial manufacturing, reducing timelines and supply chain risks for Australian-developed therapies.
The Broader Gene Editing Landscape
Australia’s gene editing research ecosystem spans multiple institutions and therapeutic areas. A grant awarded for gene therapy to correct achondroplasia (dwarfism) will run from January 2026 to December 2029, developing a groundbreaking single-dose CRISPR gene therapy to precisely correct the ACH mutation.
Clinical trials of CRISPR-based therapies are also being conducted in Australia. A Phase 1 trial evaluating CTX310 for refractory dyslipidemias is enrolling participants in Adelaide, investigating a lipid-lowering genetic therapy developed by CRISPR Therapeutics. Separately, Australia is leading a first-in-human trial of a cholesterol-lowering genetic therapy developed by Scribe Therapeutics, using a next-generation CRISPR-based approach known as epigenetic silencing delivered as a one-time infusion.
Manufacturing and Translation Infrastructure
The translation of gene editing discoveries into clinical therapies depends on manufacturing infrastructure. Cell Therapies Pty Ltd, co-located with Peter MacCallum Cancer Centre, provides GMP-licensed manufacturing for CAR T-cell products. The newly licensed viral vector manufacturing facility addresses another critical input for gene therapies.
This infrastructure, combined with Australia’s clinical trial capabilities and regulatory framework, positions the country as an attractive location for early-phase gene and cell therapy trials. The ability to manufacture clinical products domestically accelerates timelines and reduces costs compared to importing investigational products from overseas.
Future Directions and Challenges
The gene editing and cell therapy field is evolving rapidly, with next-generation technologies addressing limitations of first-generation approaches. Base editing, prime editing, and epigenetic modulation offer greater precision and potentially fewer off-target effects than conventional CRISPR-Cas9.
Challenges remain in delivery, manufacturing scale-up, and long-term safety monitoring. The complexity of personalised therapies—where each patient’s cells are genetically modified—creates manufacturing and logistics challenges that require innovative solutions.
Australia’s research institutions, clinical trial infrastructure, and emerging manufacturing capability provide a strong foundation for addressing these challenges. The integration of discovery research, GMP manufacturing, and clinical trials within co-located facilities like those at Peter MacCallum Cancer Centre creates a template for accelerating translation.